Can antipsychotics such as quetiapine (Seroquel) cause restless‑leg syndrome (RLS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Antipsychotics Like Seroquel Cause Restless Leg Syndrome?

Yes, quetiapine (Seroquel) and other antipsychotics can definitively cause restless leg syndrome (RLS), and you should consider this medication as a potential culprit when evaluating any patient on antipsychotics who develops new-onset RLS symptoms.

Evidence from FDA Labeling and Clinical Reports

The FDA label for Seroquel explicitly documents restlessness and extrapyramidal symptoms as adverse reactions 1. In adolescent trials, restlessness occurred in patients treated with quetiapine, and the aggregated incidence of extrapyramidal symptoms reached 12.9% in schizophrenia patients versus 5.3% on placebo 1.

Clinical Case Evidence

Multiple case series demonstrate quetiapine-induced RLS occurring at surprisingly low doses (50-250 mg at bedtime) in a dose-dependent manner 2. Notably, RLS has been reported after even a single low dose of quetiapine 3. The literature identifies quetiapine, along with olanzapine and clozapine, as the most common antipsychotic causes of RLS 4.

Key Clinical Pattern to Recognize

The association appears particularly strong in patients with affective disorders who are also taking antidepressants 2. In one study, 41% of patients receiving antipsychotic and antidepressant drugs developed RLS 5. This is a critical clinical pearl: the combination of antipsychotics with antidepressants may synergistically increase RLS risk.

Mechanism

The pathophysiology involves dopaminergic blockade as the primary precipitator 3, 6. This is particularly interesting for quetiapine given its relatively low D2 receptor binding affinity, yet it still causes RLS, suggesting additional mechanisms may be involved including effects on iron metabolism 4.

Risk Factors to Assess

When evaluating for antipsychotic-induced RLS, look for:

  • Family history of RLS (genetic predisposition) 5, 6
  • Older age 7
  • Gastrointestinal diseases 7
  • Higher medication doses 7
  • Concurrent use of ≥2 psychotropic drugs (especially antidepressants) 2, 7
  • Smoking history 5

Critical Differential Diagnosis

Do not confuse RLS with akathisia or illness-related agitation 6. This distinction is essential:

  • RLS: Uncomfortable leg sensations, worse at rest/night, relieved by movement, follows circadian pattern
  • Akathisia: Subjective inner restlessness, constant need to move, not circadian, not localized to legs
  • Agitation: Related to underlying psychiatric condition, not movement-responsive

Management Algorithm

  1. First-line approach: Reduce the quetiapine dose or discontinue if clinically feasible 8, 7

  2. If antipsychotic must be continued:

    • Consider switching to agents with lower RLS association (trazodone and haloperidol showed less association in one study 5, though haloperidol carries other movement disorder risks)
    • Aripiprazole may be considered as an alternative given its partial dopamine agonist properties 8
  3. Adjunctive treatment if switching is not possible: Add clonazepam before the antipsychotic dose 8

  4. Avoid: Do not add dopamine agonists (pramipexole, ropinirole) as first-line since the 2025 AASM guidelines suggest against their standard use due to augmentation risk [9-9]

Important Caveats

  • The diagnosis of antipsychotic-induced RLS remains challenging in clinical practice 4
  • Carefully exclude RLS mimics: neuropathy, nocturnal leg cramps, positional discomfort, growing pains in children 9
  • Prevention relies on using the lowest effective antipsychotic dose and avoiding polypharmacy when possible 7
  • Document baseline movement symptoms before initiating antipsychotics to distinguish drug-induced from pre-existing RLS

The evidence clearly establishes that quetiapine and other antipsychotics cause RLS through dopaminergic mechanisms, with particular vulnerability in patients on concurrent antidepressants. Dose reduction or discontinuation is the primary management strategy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.